Genomics multiplexing platform company ChromaCode has commercially introduced the High Definition PCR (HDPCR)-based non-small-cell lung cancer (NSCLC) assay.
Leveraging amplitude modulation and multi-spectral encoding, the assay panel identifies actionable NSCLC variants in nine relevant genes from only low-sample input.
Claiming to offer cloud-based analysis and reduce workflow complexity, the assay can generate results in less than four hours.
HDPCR technology is an advanced method that enables the multiplexing of actionable biomarkers in a single, fast and cost-effective assay for different sample types on standard laboratory dPCR platforms. It has applications in oncology, organ transplant monitoring and other genomic areas.
ChromaCode Cloud complements HDPCR by delivering valuable insights and improving lab performance.
Serving as an integrated platform, this cloud-based solution is claimed to enable seamless result analysis, secure data management and efficient reporting.
ChromaCode CEO Mark McDonough said: “The ChromaCode team is committed to positively impacting both the survival rates and the quality of life of the patients that we are privileged to serve.
“We endeavour to do this by providing our physician and laboratory partners with high quality, fast, lower cost solutions such as the ChromaCode HDPCR NSCLC assay to expand options for faster, targeted treatment.”
The most common cancer of the lung, NSCLC constitutes approximately 85% of the over 230,000 annual lung cancer diagnoses in the US per annum and the five-year survival rate stands at 25.4%, as per the National Cancer Institute.
